MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gemcitabine is a primary chemotherapy for pancreatic cancer, but drug resistance leads to patient relapse.
• The upstream regulators, particularly non-coding RNAs, influencing gemcitabine resistance in pancreatic cancer remain unclear.
• Previous research identified FKBP51-mediated AKT inhibition as a link to gemcitabine response.

Purpose of the Study:

• To delineate the miRNA expression profile associated with gemcitabine response in pancreatic cancer.
• To identify novel non-coding RNA regulators of chemoresistance.
• To elucidate the role of miR-30a in regulating the SNAI1-IRS1-AKT signaling pathway and gemcitabine sensitivity.

Main Methods:

• miRNA expression profiling to identify key signaling pathways.
• In vitro and in vivo experiments to validate the regulatory role of miR-30a.
• Analysis of clinical pancreatic cancer tissues to correlate miR-30a expression with patient survival.

Main Results:

• MiR-30a was identified as a critical node in the gemcitabine response network.
• MiR-30a directly targets SNAI1, subsequently regulating IRS1 to activate AKT and ERK signaling.
• Downregulation of miR-30a in pancreatic tumors correlated with poorer patient survival.
• A feedback loop involving AKT-FOXO3a and miR-30a was identified.

Conclusions:

• MiR-30a acts as an upstream regulator of the AKT pathway, significantly impacting pancreatic cancer development and chemoresistance.
• Restoring miR-30a levels may represent a therapeutic strategy to enhance gemcitabine efficacy in pancreatic cancer.
• This study highlights the crucial role of non-coding RNAs in mediating chemoresistance and provides a potential therapeutic target.